Graphium Biosciences

Graphium Biosciences, Inc, a wholly-owned subsidiary of Malachite Innovations, is developing a novel pharmaceutical grade cannabinoid drug poised to disrupt the $20 billion inflammatory bowel disease market. Graphium has invented a proprietary patent-pending glycosylation technology that attaches glucose to cannabinoids, thereby creating a glycosylated cannabinoid that is anticipated to unlock the rebalancing effects of the endocannabinoid system to reduce gastrointestinal inflammation but without any psychoactive side effects. Graphium has developed over 250 glycosylated cannabinoids and endocannabinoids covered by patent filings. Graphium’s leading drug candidate (VBX-100), a glycosylated-THC molecule, has been awarded an Orphan Drug Designation by the FDA for pediatric ulcerative colitis. Graphium has developed a drug development plan that advances VBX-100 through its remaining animal studies and Phase I and II clinical studies over a three-year period once sufficient funding is obtained.